The underlying basis of cancer is genomic alterations which inevitably result in dysregulated protein activity that drives the disease. Accordingly, while a powerful tool to uncover underlying mechanisms of disease, the utility of genomics for patient selection is limited when it comes to drug-response prediction in oncology. Genomic biomarkers have only proven useful for patient selection in the small subset of cancers (~5%) caused by single gene alterations or simple synthetic lethal context. However, the vast majority of cancers contain multiple, complex genomic alterations resulting in the dysregulated tumor-driving protein activity.
Proteomic biomarkers enable direct measurement of disease-driving mechanisms independent of target gene alterations, and allows for accurate matching with the drug mechanism of action.
Acrivon’s Predictive Precision Proteomics (AP3) platform takes proteomics one step further. Our transformative method is widely applicable allowing us to deliver impactful therapies to precisely the right patients.